Regulation of Insulin-Like Growth Factor (IGF)-I Action by Matrix Metalloproteinase-3 Involves Selective Disruption of IGF-I/IGF-Binding Protein-3 Complexes

Endocrinology

Volumn 145, Issue 2, 2004, Pages 620-626

  Fowlkes, John L ^a   Serra, Delila M ^b   Bunn, R Clay ^a   Thrailkill, Kathryn M ^a   Enghild, Jan J ^c   Nagase, Hideaki ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c AARHUS UNIVERSITY   (Denmark)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR ANTIBODY; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

3T3 CELLS; ANIMALS; CELL DIVISION; FIBROBLASTS; GENE EXPRESSION; GLYCOSYLATION; HOMEOSTASIS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MATRIX METALLOPROTEINASE 3; MICE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFECTION; TYROSINE;

EID: 0842313088     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0636     Document Type: Article

References (35)

1. Jones JI, Clemmons DR 1995 Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34
2. Rechler MM 1993 Insulin-like growth factor binding proteins. Vitam Horm 47:1-114
3. Firth SM, Baxter RC 2002 Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854
4. LeRoith D, Werner H, Beitner-Johnson D, Roberts Jr CT 1995 Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16: 143-163
5. D'Ercole AJ 1996 Insulin-like growth factors and their receptors in growth. Endocrinol Metab Clin North Am 25:573-590
6. Fowlkes JL 1997 Insulin-like growth factor-binding protein proteolysis: an emerging paradigm in insulin-like growth factor physiology. Trends Endocrinol Metab 8:299-306
7. Bunn RC, Fowlkes JL 2003 Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab 14:176-181
8. Fowlkes JL, Thrailkill KM, Serra DM, Suzuki K, Nagase H 1995 Matrix metalloproteinases (MMPS) as insulin-like growth factor binding protein (IG-FBP)-degrading proteinases. Prog Growth Factor Res 6:255-263
9. Coussens LM, Werb Z 1996 Matrix metalloproteinases and the development of cancer. Chem Biol 3:895-904
10. Sternlicht MD, Werb Z 2001 How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516
11. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H 1994 Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem 269:25742-25746
12. Thrailkill KM, Quarles LD, Nagase H, Suzuki K, Serra DM, Fowlkes JL 1995 Characterization of insulin-like growth factor-binding protein-5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology 128:3144-3151
13. Fowlkes JL, Suzuki K, Nagase H, Thrailkill KM 1994 Proteolysis of insulin-like growth factor-binding protein-3 during rat pregnancy: a role for matrix metalloproteinases. Endocrinology 135:2810-2813
14. Martin DC, Fowlkes JL, Babic B, Khokha R 1999 Insulin-like growth factor n signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol 146:881-892
15. Sommer A, Spratt SK, Tatsuno GP, Tressel T, Lee R, Maack CA 1993 Properties of glycosylated and non-glycosylated human recombinant IGF binding protein-3 IGFBP-3). Growth Regul 3:46-49
16. Benbow U, Buttice G, Nagase H, Kurkinen M 1996 Characterization of the 46-kDa intermediates of matrix metalloproteinase 3 (stromelysin 1) obtained by site-directed mutation of phenylalanine 83. J Biol Chem 271:10715-10722
17. Huang W, Suzuki K, Nagase H, Arumugam S, Van Doren SR, Brew K 1996 Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield in E. coli. FEBS Lett 384:155-161
18. Hernandez-Sanchez C, Blakesley V, Kalebic T, Herman L, LeRoith D 1995 The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. J Biol Chem 270:29176-29181
19. Visse R, Nagase H 2003 Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839
20. Flier JS, Usher F, Moses AC 1986 Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts. Proc Natl Acad Sci USA 83:664-668
21. Werb Z 1997 ECM and cell surface proteolysis: regulating cellular ecology. Cell 91:439-442
22. Flaumenhaft R, Rifkin DB 1991 Extracellular matrix regulation of growth factor and protease activity. Curr Opin Cell Biol 3:817-823
23. Fowlkes JL, Winkler MK 2002 Exploring the interface between metallo-proteinase activity and growth factor and cytokine bioavailability. Cytokine Growth Factor Rev 13:277-287
24. Mañes S, Mira E, del Mar Barbacid M, Ciprés A, Fernández-Resa P, Buesa JM, Mérida I, Aracil M, Márquez G, Martínez-AC 1997 Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 272:25706-25712
25. Sympson CJ, Talhouk RS, Alexander CM, Chin JR, Clift SM, Bissell MJ, Werb Z 1994 Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol 125:681-693
26. Sympson CJ, Bissell MJ, Werb Z 1995 Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin Cancer Biol 6:159-164
27. Sledge GW, Qulali M, Goulet R, Bone EA, Fife R 1995 Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87:1546-1550
28. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR 1993 A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087-2091
29. Chirivi RG, Garofalo A, Crimmin MJ, Bawden LJ, Stooacciaro A, Brown PD Giavazzi R 1994 Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460-464
30. Naito K, Kanbayashi N, Nakajima S, Murai T, Arakawa K, Nishimura S, Okuyama A 1994 Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer 58:730-735
31. Powell WC, Matrisian LM 1996 Complex roles of matrix metalloproteinases in tumor progression. Curr Top Microbiol Immunol 213:1-21
32. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM 1994 Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54: 4726-4728
33. Campbell PG, Novak JF, Yanosick TB, McMaster JH 1992 Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 130:1401-1412
34. Lalou C, Lassarre C, Binoux M 1996 A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137:3206-3212
35. Woessner Jr JF 1994 The family of matrix metalloproteinases. Ann NY Acad Sci 732:11-21